Accounts of use for depression, ADD/ADHD, fibromyalgia, chronic fatigue (off-label). Metabolic precursor to modafinil; takes 1 hr to kick in, hard on liver. Not "controlled" like modafinil/Provigil.
Unlike conventional stimulants, no anxiety, agitation and insomnia; selectively stimulates brain's adrenergic receptors for norepinephrine (noradrenaline), a neurotransmitter linked to alertness, learning, and memory.
Rapidly restores vigilance and alertness in older people and the physically and mentally tired. Has a powerful antidepressant action far superior to that of fluoxetine (Prozac) and clomipramine (Anafranil) and is without any serious side effects. Adrafin
For narcolepsy, or off-label for depression, night-shift work, ADHD/ADD...a prodrug, metabolizes to modafinil (Provigil®), resulting in nearly identical pharmacological effects, takes 45-60 minutes to reach active levels in bloodstream.
Super eugeroic 'armodafinil' (Nuvigil), by modafinil’s creator, Cephalon, is FDA-approved. Ampakine CX717 from Cortex is in clinical trials. Both drugs promise even longer periods of wakefulness.
Researchers say that ampakines, which extend waking times and enhance cognitive function, did not appear to be linked to side effects such as hyperactivity, distorted thinking or extended wakefulness. Samuel Deadwyler, of who led the Wake Forest Universit
Ampakines capable of improving cognition by enhancing brain activity under normal circumstances may also have the potential to reduce the harmful or unwanted effects of sleep deprivation. (CX717 by Cortex Pharmaceuticals)
Armodafinil (Nuvigil®) is an eugeroic drug made by Cephalon, FDA-approved 6/15/2007. Clinical trials for its use in bipolar disorder, cognition in schizophrenia, excessive fatigue in Parkinson's & cancer, begin. Patent expires 2023.
Modafinil induces wakefulness, but its dopamine-releasing action in the nucleus accumbens is weak and dose-dependent; no likelihood of euphoric response ('abuse potential').